Incyte’s New Therapy Shows Signs Of ‘Disease-Modifying’ Potential In Rare Blood Cancer

All NewsDecember 8, 2025

Early ASH 2025 data shows Incyte’s INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent